Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Johnson and Johnson
Express Scripts
AstraZeneca

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR UNASYN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Unasyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00760006 ↗ Preventing Complications in Cleft Palate Repair With Antibiotics Completed Children's Hospital of Pittsburgh Phase 2 2008-05-01 The primary objective of this study is to determine the efficacy of administering a single dose of preoperative antibiotics to prevent complications in patients undergoing primary closure of a cleft secondary palate. Secondary objective of this study is to evaluate the effects of preoperative antibiotics administered on post operative outcome following primary closure of cleft secondary palate. The study aims to assess the efficacy of prophylactic antibiotics in cleft surgery to - decrease the incidence of surgical sight infections - speed the progression of postoperative healing - improve the final quality of wound healing achieved - decrease the rate of palatal fistula formation
NCT00760006 ↗ Preventing Complications in Cleft Palate Repair With Antibiotics Completed Joseph Losee Phase 2 2008-05-01 The primary objective of this study is to determine the efficacy of administering a single dose of preoperative antibiotics to prevent complications in patients undergoing primary closure of a cleft secondary palate. Secondary objective of this study is to evaluate the effects of preoperative antibiotics administered on post operative outcome following primary closure of cleft secondary palate. The study aims to assess the efficacy of prophylactic antibiotics in cleft surgery to - decrease the incidence of surgical sight infections - speed the progression of postoperative healing - improve the final quality of wound healing achieved - decrease the rate of palatal fistula formation
NCT00879190 ↗ Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis Completed Stanford University Phase 2/Phase 3 2009-05-01 Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters) surrounding the baby inside of a pregnant woman prior to delivery. This infection is somewhat common and is routinely treated with antibiotics given to the mother both before and after the baby is born. Currently it is not known what is the best choice of antibiotics to treat this type of infection, but commonly used treatments include Unasyn (ampicillin/sulbactam) or ampicillin/gentamicin. We plan to compare these two different antibiotic regimens to see if one is better than the other at treating and preventing bad outcomes from chorioamnionitis in women and babies.
NCT01118403 ↗ Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients Withdrawn Hospital Pablo Tob√≥n Uribe Phase 4 2011-03-01 This study seeks to assess whether coma patients really benefit from the use of antibiotics as a prophylactic for reducing the incidence of early ventilator-associated pneumonia in this population group. For this we consider the use of ampicillin sulbactam antibiotic which has a low ability to induce resistance, efficacy and safety observed during the time that has been used, even in patients with neurosurgical pathology, and to be broadly available in our environment. Our hypothesis is that neurological patients in coma state, requiring mechanical ventilation, the application of antibiotic prophylaxis compared with placebo reduces the incidence of early ventilator-associated pneumonia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Unasyn

Condition Name

Condition Name for Unasyn
Intervention Trials
Cleft Palates 1
Infection 1
Jaw Fractures 1
Lung Abscess 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Unasyn
Intervention Trials
Pneumonia 3
Fractures, Bone 2
Fractures, Open 1
Chorioamnionitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Unasyn

Trials by Country

Trials by Country for Unasyn
Location Trials
Japan 15
United States 4
Colombia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Unasyn
Location Trials
Texas 1
Ohio 1
California 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Unasyn

Clinical Trial Phase

Clinical Trial Phase for Unasyn
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Unasyn
Clinical Trial Phase Trials
Completed 4
Terminated 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Unasyn

Sponsor Name

Sponsor Name for Unasyn
Sponsor Trials
Pfizer 2
Children's Hospital of Pittsburgh 1
Joseph Losee 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Unasyn
Sponsor Trials
Other 6
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
AstraZeneca
Moodys
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.